Container closure integrity testing methods compared

Quick answer: Container closure integrity testing (CCIT) asks whether a sealed pack keeps microbes and gas out, and the pharmacopoeial preference is for deterministic methods (vacuum decay, high voltage leak detection, laser headspace, helium leak) over probabilistic ones such as dye ingress. No single method covers every container, fill state and life-cycle stage, so the choice is made per pack with your quality and regulatory teams.

This piece rests mainly on statements from test labs and instrument makers, plus pharmacopoeial and regulatory texts. Lighthouse Instruments (laser headspace) and Wilco (leak-test equipment) sell instruments; Sharp Services and Westpak sell testing services, and Westpak says it offers only vacuum decay among the deterministic methods. Independent comparison data is noted where it exists, and it is thin.

What integrity means, and why the method matters

Integrity is about the whole assembly: glass or polymer container, elastomer stopper or plunger, crimp or cap, and the seal between them. A vial can pass visual inspection and still leak at the stopper-glass interface under the wrong crimp force or after a freeze cycle.

The USP chapter on package integrity, USP <1207> and its subchapters, was rewritten and, per a Eurofins technical brochure, issued as <1207>, <1207.1> and <1207.2> in 2016. That version states that deterministic methods are preferred over probabilistic ones because they give reproducible, predictable results at low detection limits.

A deterministic method, as one AAPS chapter presentation puts it, measures leakage through a predictable physical mechanism and yields objective, quantitative data. Probabilistic methods depend more on the operator and on chance; the ECA Academy notes that a bubble test or blue bath can still serve well for locating a leak. The American Pharmaceutical Review adds that the revision dropped the requirement to compare other CCI assays against a microbial ingress challenge.

What regulators say as of 1 November 2026

On the EU side, Annex 1 on sterile products (finalised in 2022) separates containers closed by fusion from those closed mechanically. Its text calls for 100 percent integrity testing of fusion-sealed containers such as ampoules and bags, and says samples of containers closed by other methods should be checked, with test frequency based on knowledge and experience of the container and closure system.

The ECA position paper reads this to mean that vials and prefilled syringes rely on validated process controls and risk-based CCIT sampling. It also points to the sections on vacuum verification for lyophilised products and on transport validation.

In the US, the FDA announced a draft guidance titled “Container Closure Systems for Human Drugs and Biological Products” in the Federal Register on 14 August 2026. Once finalised, it would replace the 1999 guidance and the 2002 Questions and Answers document. Packaging Digest reports that the draft raises expectations for CCIT, particularly for sterile products.

Comments were open until 13 October 2026, per the ECA Academy. Our calculation: 17 days left in August after the 14th, plus 30 in September, plus 13 in October, gives a 60-day comment window. The sources I reviewed still describe it as a draft; check the current text before citing it. This site doesn’t cover regulation in depth; for EU packaging law see ppwreu.org.

The methods side by side

The table summarises how the cited sources describe each method. Sensitivity is the smallest leak diameter a source says the method can detect, which varies with container, fill, defect type and validation. Treat the figures as typical claims, not specifications.

Method USP <1207> class Destructive? Typical sensitivity (µm leak diameter) Where sources say it is used
Dye ingress / bubble emission Probabilistic Yes No consistent figure in the sources reviewed Locating leaks; legacy methods
Vacuum decay (ASTM F2338) Deterministic No About 5 Rigid containers, vials, syringes, some flexible packs
HVLD Deterministic No About 1 to 5 Liquid-filled vials, syringes, ampoules, BFS cards
Laser headspace analysis Deterministic No About 1 to 5, smaller with extra steps Containers with a headspace; oxygen-sensitive or lyophilised fills
Helium leak detection Deterministic Yes, per Sharp Services Below 0.01 to sub-micron Development, validation, leak-limit studies

Sources for the table: Wilco (HVLD, laser headspace, helium), Flexpak (vacuum decay, flexible packs) and Sharp Services (helium).

How each method works

Vacuum decay places the pack in a test chamber, draws a vacuum and watches the pressure signature. Westpak describes it as non-destructive and suited to many rigid and flexible packs, including vials and prefilled syringes. One university thesis notes that vacuum decay cannot be applied to every product type. Pressure decay is its close relative, using positive pressure instead.

HVLD passes an electrical current through a liquid-filled container; the Flexpak guide lists glass vials and prefilled syringes as typical targets. A second Flexpak guide says it is typically not viable for lyophilised or powder fills, where headspace analysis or vacuum decay is preferred instead.

Laser headspace analysis measures gas composition or pressure in the space above the product through the container wall. A US patent filing notes it is non-destructive and deterministic, but has disadvantages when a defect sits below the product level. Its logic: if oxygen is found in a container filled under vacuum, air has entered through a defect.

Helium leak detection fills or surrounds the pack with helium and uses a mass spectrometer to detect escape. Lighthouse Instruments says it is often used for package development studies and for maximum allowable leakage investigations, with complexity and throughput limiting wider use.

Why the sensitivity numbers don’t line up

Pick up three vendor pages and you will find three ranges. Wilco gives laser headspace as about 1 to 5 µm. Lighthouse Instruments, which sells the technology, says its sensitivity is similar to helium leak detection. Neither is independent test data.

The gap is explained by method conditions. Headspace methods change with headspace volume and fill; HVLD changes with fill volume and conductivity; and helium results change with how the pack is filled with tracer gas. A single “µm” figure hides all of that.

Our calculation, using Sharp Services’ helium figure (below 0.01 µm) against Flexpak’s vacuum decay figure (about 5 µm): 5 ÷ 0.01 = 500, so the quoted gap in smallest detectable leak diameter is at least 500 times. That is a ratio of two vendor claims from different pages, not a measured comparison. Whether the gap matters depends on the maximum allowable leakage limit set for the product, which your team derives from the product and its risks.

Cold chain and transport add a second question

Integrity at filling is one data point; integrity after storage and shipping is another. An A3P article cites studies showing that ultracold storage temperatures can put the integrity of conventional vial and rubber stopper combinations at risk. A peer-reviewed paper on a deep-cold-stored vaccine vial system assessed residual seal force and CCI after storage at −80 °C, and links the approach to Annex 1’s wording on transport.

The A3P article also lists a deterministic headspace method developed for vials held at −80 °C. Whether a given pack tolerates a given temperature profile is a study question, not something a table can settle.

Questions to ask suppliers and your own teams

Suppliers (container, stopper, test equipment):

  • Which USP <1207> methods has this container-closure pairing been run through, and with what defect type and size?
  • What is the documented sensitivity for my fill volume, and at what conditions?
  • Does the method need modified containers, tracer gas or a special chamber per format?
  • Which components (stopper, plunger, crimp) vary lot to lot, and what is the control range?

Regulatory and quality teams:

  • Which authority text and pharmacopoeia chapters apply to this product and market, and which version is current?
  • What maximum allowable leakage limit applies, and how was it derived?
  • Is CCIT planned for release, stability, or both, and how does the plan treat shipping and storage temperature?
  • Does the autoinjector or pen, if the product is a combination product, bring device constituent parts into the same plan? The draft guidance’s scope includes combination products, per American Pharmaceutical Review.

What this means for you

Treat the method as part of the pack design, not an afterthought at the end of stability. Ask for the container-closure combination’s integrity data early, because the method that fits a liquid-filled syringe may not fit a lyophilised vial.

Read vendor sensitivity claims as marketing until you see the defect type, container and conditions behind them. When you compare methods, request a side-by-side on your own pack, run by the lab that will validate it.

This article is education only. Material, pack and method choice, and compliance with any pharmacopoeia or authority, are decided with your regulatory and quality teams.

Sources

This article is general education about packaging materials, formats and test methods. It is not regulatory, quality or medical advice. For a real product, confirm material choice, testing and compliance with your regulatory and quality teams and the applicable pharmacopoeia and authority.

Header image: illustration, AI-generated.